Scientific Advisory Board
Jaap Wieling, PhD
Jaap Wieling brings over 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research and development. He is a seasoned expert in building effective and efficient R&D and product development organizations. His comprehensive and commonsensical approach ensures the best possible way to efficacious development of candidate medicines.
From his independent position at Antaeus Biopharma, Jaap fulfills executive, board and advisor positions in startup biotech companies and (pharmaceutical) service industries since 1999. Before that he held executive and research management roles in R&D institutions and commercial research and manufacturing corporations. Jaap has been a University teacher throughout his career and he serves as an expert volunteer for non-profit organizations.
Expertise: Building R&D organizations, serial entrepreneur, extensive preclinical experience
Jaap Wieling, PhD
Jaap Wieling brings over 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research and development. He is a seasoned expert in building effective and efficient R&D and product development organizations. His comprehensive and commonsensical approach ensures the best possible way to efficacious development of candidate medicines.
From his independent position at Antaeus Biopharma, Jaap fulfills executive, board and advisor positions in startup biotech companies and (pharmaceutical) service industries since 1999. Before that he held executive and research management roles in R&D institutions and commercial research and manufacturing corporations. Jaap has been a University teacher throughout his career and he serves as an expert volunteer for non-profit organizations.
Expertise: Building R&D organizations, serial entrepreneur, extensive preclinical experience.
Hans Maag, PhD
Hans Maag, Ph.D. is a co-founder of Orfan Biotech. He started his distinguished career as a medicinal chemist at Hoffmann-LaRoche Inc in NJ, in the field of antibiotics and prostacyclins.
After moving to Syntex in Palo Alto, CA, he did research on antiviral agents with a focus on anti-HIV agents which lead to the development of Valganciclovir (ValcyteTM). After the acquisition of Syntex by Roche, Dr. Maag became VP, Chemistry, and he led many project teams, from early lead identification to preclinical (pre-IND) development. During his time at Roche Palo Alto he was also in charge of the global task force on lead generation and was responsible for the computational chemistry group.
Expertise: Drug transport mechanisms across intestinal membrane.
Hans Maag, PhD
Hans Maag, Ph.D. is a co-founder of Orfan Biotech. He started his distinguished career as a medicinal chemist at Hoffmann-LaRoche Inc in NJ, in the field of antibiotics and prostacyclins.
After moving to Syntex in Palo Alto, CA, he did research on antiviral agents with a focus on anti-HIV agents which lead to the development of Valganciclovir (ValcyteTM).
After the acquisition of Syntex by Roche, Dr. Maag became VP, Chemistry, and he led many project teams, from early lead identification to preclinical (pre-IND) development. During his time at Roche Palo Alto he was also in charge of the global task force on lead generation and was responsible for the computational chemistry group.
Expertise: Drug transport mechanisms across intestinal membrane.